New recommendations from a large, multidisciplinary consensus conference published this week in the Journal of Clinical Oncology suggest expanding use of genetic testing to guide treatment for men with prostate cancer, including the use of panel testing and testing patients with early stage disease.
In a phase II clinical trial, patients with high-grade serous ovarian cancer who were treated with berzosertib and chemotherapy lived substantially longer than did those treated with chemotherapy alone.
The phase III IMpassion031 study, evaluating Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [albumin-bound paclitaxel, nab-paclitaxel]; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chemotherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of people with early triple-negative breast cancer, regardless of PD-L1 expression.
In the ACE-CL-001 trial, data showed 97% of previously untreated CLL patients continued to respond to treatment after more than four years with no new safety signals.
A method of analysing cancer patients' blood for evidence of the disease could be up to 10 times more sensitive than previous methods, according to research funded by Cancer Research UK and published in Science Translational Medicine.
Keytruda in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma did not meet its pre-specified dual primary endpoints of overall survival or progression-free survival, compared with standard of care chemotherapy.
Researchers at the Keck School of Medicine have identified a variant in the genome that may explain why multiple men in the same family develop the disease—and could serve as a guide for screening,
New research from Mass General Cancer Center, published in JNCCN—Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission, meaning they needed assistance with activities of daily living like walking, bathing, getting dressed, or other routine tasks.
Scientists have developed a new test that can help identify people who are likely to develop hepatocellular carcinoma. The approach uses a simple blood test to check for the patient's previous exposure to certain viruses.
Yale Cancer Center scientists have developed a cell screening method for agents that alter biologic functions. This approach uses thousands of artificial proteins called “traptamers” and may help to answer research questions that are difficult to address with other cell screening methods, including the SARS-CoV-2 virus, COVID-19.
